CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 886 enrolled
Drug / intervention
Phase II: NTC015 low dose +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04759885
NCT04759885Phase 3Completed

Efficacy and Safety of mAnniTol in Bowel Preparation: Assessment of Adequacy and Presence of Intestinal levelS of Hydrogen and Methane During Elective Colonoscopy aFter mAnnitol or Standard Split 2-liter Polyethylene Glycol Solution Plus asCorbaTe - a Phase II/III, International, Multicentre, Randomized, Parallel-group, endoscOpist-bliNded, Dose-finding/Non-inferiority Study - SATISFACTION

NTC srl·interventional·Posted Feb 18, 2021·Updated Dec 8, 2025

In Brief

A Phase 3 clinical trial evaluating Phase II: NTC015 low dose, Phase II: NTC015 medium dose, and 3 other interventions for Elective Colonoscopy. Completed, enrolled 886 participants across 35 sites in 4 countries.

Detailed Summary

The purpose of this dose finding/comparative efficacy study is to first single out the most appropriate dose of mannitol for bowel preparation (phase II) and, subsequently, demonstrate the non-inferiority of the efficacy of single dose mannitol vs standard split 2L PEG ASC (Moviprep®) (phase III) in bowel preparation for colonoscopy .

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Germany, Italy, Russia
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedFeb 18, 2021
Enrollment StartJun 18, 2020
Primary CompletionJul 16, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.4 years ago

Interventions

Phase II: NTC015 low dosedrug

Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration

Phase II: NTC015 medium dosedrug

Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration

Phase II: NTC015 high dosedrug

Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration

Phase III: NTC015 selected dosedrug

Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration

Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC)drug

The instructions for product administration are followed according to the Summary of Product Characteristics. One treatment consists of two litres of Moviprep® taken according to split-dose regimen. The first litre of Moviprep® is prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution. The reconstituted solution must be drunk over a period of one to two hours the evening before colonoscopy. About half a litre of clear liquid should be drunk in the next hour to prevent dehydration according to local practice at the centre. This process should be repeated with a second litre of Moviprep® prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution in the early morning of the day of the procedure.